“We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals (MIST). “Our launch preparations are well underway. We have resources secured to make CARDAMYST available to patients and healthcare providers mid-year, assuming FDA approval.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule
- Milestone Pharmaceuticals Prepares for CARDAMYST Launch
- Milestone receives notice of allawance from USPTO on etripamil nasal spray
- Milestone Pharmaceuticals to host Commercial Launch Plan investor event
- Milestone Pharmaceuticals provides 2025 corporate outlook